Publicacións en colaboración con investigadores/as de Hospital Sagrado Corazón (8)

2021

  1. BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib

    JTO Clinical and Research Reports, Vol. 2, Núm. 3

2019

  1. Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non–Small Cell Lung Cancer

    Journal of Thoracic Oncology, Vol. 14, Núm. 2, pp. 304-310

  2. BRAF mutations classes I, II, and III in NSCLC patients included in the SLLIP trial: The need for a new pre-clinical treatment rationale

    Cancers, Vol. 11, Núm. 9

  3. EGFR first- and second-generation TKIs-there is still place for them in EGFR-mutant NSCLC patients

    Translational Cancer Research, Vol. 8, pp. S23-S47

  4. Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC)

    EBioMedicine, Vol. 39, pp. 207-214

  5. PIM-1 inhibition with AZD1208 to prevent osimertinib-induced resistance in EGFR-mutation positive non-small cell lung cancer

    Journal of Cancer Metastasis and Treatment, Vol. 5

2018

  1. Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC

    Translational Lung Cancer Research, Vol. 7, Núm. 6, pp. 691-702

  2. Strategies for first-line immunotherapy in squamous cell lung cancer: Are combinations a game changer?

    Translational Lung Cancer Research, Vol. 7, pp. S198-S201